Index Inclusion: Immuneering Corporation is set to be added to the Nasdaq Biotechnology Index effective December 22, 2025, marking a significant recognition in the biotech sector that could enhance its market visibility and investor confidence.
Market Entry Standards: The Nasdaq Biotechnology Index requires companies to meet minimum market capitalization and average daily trading volume, and Immuneering's inclusion indicates its compliance with these industry standards, thereby strengthening its competitive position in the biopharmaceutical field.
Clinical Trial Progress: Immuneering is developing a novel category of cancer medicines, with its lead candidate, atebimetinib, expected to begin dosing in a Phase 3 trial for first-line pancreatic cancer in mid-2026, which, if successful, could significantly improve patient survival rates and quality of life.
Innovative Drug Development: The company focuses on developing Deep Cyclic Inhibitors aimed at enhancing durability and tolerability across various cancer indications, with the potential to drive revenue growth and increase market share through new drug launches.
IMRX
$5.86+Infinity%1D
Analyst Views on IMRX
Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.780
Low
11.00
Averages
17.60
High
30.00
Current: 5.780
Low
11.00
Averages
17.60
High
30.00
Leerink
Outperform
initiated
$15
2025-10-31
Reason
Leerink
Price Target
$15
2025-10-31
initiated
Outperform
Reason
Leerink initiated coverage of Immuneering with an Outperform rating and $15 price target. The firm notes lead asset atebimetinib is an allosteric MEK inhibitor that has shown compelling Phase 2 activity in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma, a tumor type in which over 90% of patients are driven by aberrant, constitutive MAPK signaling. Leerink thinks DCI, which departs from conventional, continuous kinase inhibition and uses high dose, pulsatile blockade, introduces mechanistic risk. However, it sees significant upside if efficacy and tolerability are confirmed in the pivotal trial by allowing a more tolerable approach to MEK inhibition. The firm views atebi as a blockbuster+ agent in PDAC with $2.4B peak revenues, representing $14/share in its model.
Mizuho
NULL -> Outperform
maintain
$10 -> $12
2025-10-29
Reason
Mizuho
Price Target
$10 -> $12
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Immuneering to $12 from $10 and keeps an Outperform rating on the shares.
Oppenheimer
Jay Olson
Outperform
maintain
$21 -> $30
2025-09-25
Reason
Oppenheimer
Jay Olson
Price Target
$21 -> $30
2025-09-25
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on Immuneering to $30 from $21 and keeps an Outperform rating on the shares after the company surprised with an earlier-than-expected update on atebimetinib in 1L PDAC. The firm says that "the sooner the better when data are this strong," exceeding expectations that it had recently laid out. Encouragingly, the 9-month overall survival rate, a key focus of the update, achieved 86%, well above Oppenheimer's 75% expectation and clearly separated from historical GnP benchmarks. The favorable OS outcome was further supported by an impressive 53% PFS rate at 9 months, which altogether reinforces the efficacy contribution of atebimetinib on top of mGnP. Moreover, atebimetinib+mGnP continued to demonstrate a favorable tolerability profile, the firm adds.
Mizuho
NULL
to
Outperform
maintain
$8 -> $10
2025-06-19
Reason
Mizuho
Price Target
$8 -> $10
2025-06-19
maintain
NULL
to
Outperform
Reason
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
